C9016 — Injection, triptorelin extended release, 3.75 mg
C9016 is a HCPCS Level II code for injection, triptorelin extended release, 3.75 mg. It belongs to the Outpatient Prospective Payment System section. It was terminated on December 31, 2018 and is not valid on new claims.
This code has been terminated
CMS terminated C9016 on December 31, 2018. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9016
- Long descriptor
- Injection, triptorelin extended release, 3.75 mg
- Short descriptor
- Inj, triptorelin ext rel
- Added
- January 1, 2018
- Terminated
- December 31, 2018
- BETOS
- O1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9016
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9016 is not quite right, the correct code is very often within a few positions of it.
- C8933Magnetic resonance angiography without contrast followed by with contrast, spinal canal and contents
- C8934Magnetic resonance angiography with contrast, upper extremity
- C8935Magnetic resonance angiography without contrast, upper extremity
- C8936Magnetic resonance angiography without contrast followed by with contrast, upper extremity
- C8937Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)
- C8957Intravenous infusion for therapy/diagnosis; initiation of prolonged infusion (more than 8 hours), requiring use of portable or implantable pump
- C9014Injection, cerliponase alfa, 1 mgterminated
- C9015Injection, c-1 esterase inhibitor (human), haegarda, 10 unitsterminated
- C9021Injection, obinutuzumab, 10 mgterminated
- C9022Injection, elosulfase alfa, 1mgterminated
- C9023Injection, testosterone undecanoate, 1 mgterminated
- C9024Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabineterminated
- C9025Injection, ramucirumab, 5 mgterminated
- C9026Injection, vedolizumab, 1 mgterminated
- C9027Injection, pembrolizumab, 1 mgterminated
- C9028Injection, inotuzumab ozogamicin, 0.1 mgterminated
Questions about C9016
What is HCPCS code C9016?
C9016 is a HCPCS Level II code for injection, triptorelin extended release, 3.75 mg. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9016?
The CMS HCPCS file marks C9016 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9016 still valid?
No. C9016 was terminated on December 31, 2018 and should not be used on new claims.